Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $90.77 million for the quarter.

Organogenesis Price Performance

Shares of ORGO opened at $4.91 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a market cap of $622.73 million, a PE ratio of -81.83 and a beta of 1.79. The firm’s 50 day moving average price is $4.55 and its 200 day moving average price is $3.81. Organogenesis has a twelve month low of $2.21 and a twelve month high of $6.71.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Insider Activity

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company’s stock, valued at $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 36.90% of the stock is currently owned by insiders.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.